Billing and Coding: Positron Emission Tomography Scans Coverage - R23

This coverage article has been revised and published for notice under contract numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories).

Effective Date: April 01, 2021
Summary of Article Changes: Added the following diagnosis codes under Group 4 List I; Group 5 List II; Group 6 List III, Group 7 List IV and Group 9 List VI effective 10/01/2020 per Change Request 12027.

  • Group 4 List I
    • D47.Z2 - Castleman disease
    • D47.Z9 - Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
    • G13.0 - Paraneoplastic neuromyopathy and neuropathy
  • Group 5 List II
    • C79.51 - Secondary malignant neoplasm of bone
    • G13.0 - Paraneoplastic neuromyopathy and neuropathy
  • Group 6 List III
    • C94.40 - Acute panmyelosis with myelofibrosis not having achieved remission
    • C94.41 - Acute panmyelosis with myelofibrosis, in remission
    • C94.42 - Acute panmyelosis with myelofibrosis, in relapse
    • G13.0 - Paraneoplastic neuromyopathy and neuropathy
  • Group 7 List IV
    • G13.0 - Paraneoplastic neuromyopathy and neuropathy
  • Group 9 List VI
    • G13.0 - Paraneoplastic neuromyopathy and neuropathy

Visit the Noridian Medicare Coverage Articles webpage and scroll to the bottom of the page to view this Future article available in the CMS MCD.

            Last Updated Mon, 30 Nov 2020 19:07:59 +0000